货号:GS40754
Ublituximab is a glycoengineered chimeric monoclonal antibody targeting CD20, a surface protein on B cells. Its modified Fc region enhances binding to activating FcγRIIIa receptors on immune effector cells (e.g., natural killer cells), promoting antibody-dependent cellular cytotoxicity (ADCC). It is approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) and multiple sclerosis (MS).
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
冉凯凯